Home  »  Trending   »  Vir Biotechnology Inc. (VIR) Stock: Understanding ...

Vir Biotechnology Inc. (VIR) Stock: Understanding the Volatility

The stock of Vir Biotechnology Inc. (VIR) has gone up by 7.48% for the week, with a 5.24% rise in the past month and a -1.04% drop in the past quarter. The volatility ratio for the week is 3.22%, and the volatility levels for the past 30 days are 3.62% for VIR. The simple moving average for the past 20 days is 7.47% for VIR’s stock, with a 8.53% simple moving average for the past 200 days.

Is It Worth Investing in Vir Biotechnology Inc. (NASDAQ: VIR) Right Now?

and a 36-month beta value of 0.27. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


The average price predicted for Vir Biotechnology Inc. (VIR) by analysts is $47.75, which is $22.98 above the current market price. The public float for VIR is 114.86M, and at present, short sellers hold a 4.09% of that float. On May 24, 2023, the average trading volume of VIR was 985.62K shares.

VIR) stock’s latest price update

Vir Biotechnology Inc. (NASDAQ: VIR) has experienced a rise in its stock price by 3.85 compared to its previous closing price of 25.74. However, the company has seen a gain of 7.48% in its stock price over the last five trading days. Barron’s reported on 10/04/22 that Vir Biotechnology’s $1 Billion Government Deal Lifts the Stock

VIR Trading at 10.58% from the 50-Day Moving Average

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.89% of loss for the given period.

Volatility was left at 3.62%, however, over the last 30 days, the volatility rate increased by 3.22%, as shares surge +7.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.54% upper at present.

During the last 5 trading sessions, VIR rose by +7.48%, which changed the moving average for the period of 200-days by -11.40% in comparison to the 20-day moving average, which settled at $24.96. In addition, Vir Biotechnology Inc. saw 5.61% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at VIR starting from SVF Endurance (Cayman) Ltd, who sale 91,896 shares at the price of $25.72 back on May 22. After this action, SVF Endurance (Cayman) Ltd now owns 17,453,036 shares of Vir Biotechnology Inc., valued at $2,363,905 using the latest closing price.

SVF Endurance (Cayman) Ltd, the 10% Owner of Vir Biotechnology Inc., sale 91,651 shares at $25.38 during a trade that took place back on May 19, which means that SVF Endurance (Cayman) Ltd is holding 17,544,932 shares at $2,326,231 based on the most recent closing price.

Stock Fundamentals for VIR

Current profitability levels for the company are sitting at:

  • +51.56 for the present operating margin
  • +89.99 for the gross margin

The net margin for Vir Biotechnology Inc. stands at +31.92. The total capital return value is set at 44.13, while invested capital returns managed to touch 27.39. Equity return is now at value -7.10, with -5.30 for asset returns.

Based on Vir Biotechnology Inc. (VIR), the company’s capital structure generated 6.16 points at debt to equity in total, while total debt to capital is 5.80. Total debt to assets is 4.19, with long-term debt to equity ratio resting at 5.96. Finally, the long-term debt to capital ratio is 5.61.

When we switch over and look at the enterprise to sales, we see a ratio of 2.60, with the company’s debt to enterprise value settled at 0.11. The receivables turnover for the company is 4.18 and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.


To sum up, Vir Biotechnology Inc. (VIR) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.